Dashboard
Manage Tickers

SMMT Summit Therapeutics Inc.

Nasdaq summittxinc.com


$ 19.36 $ 0.53 (2.83 %)    

Friday, 24-Oct-2025 19:55:11 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 19.28
$ 19.87
$ 19.15 x 250
$ 20.00 x 260
$ 19.16 - $ 20.12
$ 15.55 - $ 36.91
3,776,668
na
14.35B
$ 0.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-20-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-24-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-01-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-31-2021 12-31-2020 10-K
21 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

guggenheim-reiterates-buy-on-summit-therapeutics-maintains-40-price-target
Guggenheim Reiterates Buy on Summit Therap...
10/22/2025 13:14:27

Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.

summit-therapeutics-accepts-offers-from-investors-to-purchase-2668m-shares-at-1874share-raising-500m-in-proceeds
Summit Therapeutics Accepts Offers From In...
10/22/2025 12:04:51

barclays-maintains-underweight-on-summit-therapeutics-raises-price-target-to-16
Barclays Maintains Underweight on Summit T...
10/21/2025 12:50:08

Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Underweight and raises the price target fro...

hc-wainwright--co-maintains-buy-on-summit-therapeutics-lowers-price-target-to-40
HC Wainwright & Co. Maintains Buy on Summi...
10/21/2025 11:08:08

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the pri...

citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-40
Citigroup Maintains Buy on Summit Therapeu...
10/20/2025 15:33:35

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

whats-going-on-with-summit-therapeutics-stock-on-monday
What's Going On With Summit Therapeutics S...
10/20/2025 14:05:00

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late...

jmp-securities-reiterates-market-outperform-on-summit-therapeutics-maintains-40-price-target
JMP Securities Reiterates Market Outperfor...
10/20/2025 13:39:02

JMP Securities analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains ...

retail-investors-top-stocks-with-earnings-this-week-tesla-netflix-intel-and-more
Retail Investors' Top Stocks With Earnings...
10/20/2025 11:53:01

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

summit-therapeutics-q3-adj-eps-013-inline
Summit Therapeutics Q3 Adj. EPS $(0.13), I...
10/20/2025 10:52:59

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This...

summit-therapeutics-said-that-based-on-harmoni-trial-data-it-plans-to-submit-a-biologics-license-application-for-ivonescimab-plus-chemotherapy-for-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer-in-q4-of-2025
Summit Therapeutics Said That Based On HAR...
10/20/2025 10:48:28

Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study ResultsExpansion of Summit'...

Core News & Articles
Earnings Scheduled For October 20, 2025
10/20/2025 08:32:45

reported-sunday-summit-announces-ivonescimab-achieved-median-progression-free-survival-of-1114-months-compared-to-690-months-for-tislelizumab-plus-chemotherapy-in-landmark-harmoni-6-trial
Reported Sunday, Summit Announces Ivonesci...
10/20/2025 07:16:07

Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti...

an-overview-of-summit-therapeuticss-earnings
An Overview of Summit Therapeutics's Earnings
10/17/2025 14:01:21

summit-therapeutics-initiates-global-phase-iii-harmoni-gi3-trial-evaluating-ivonescimab-plus-chemotherapy-in-metastatic-colorectal-cancer
Summit Therapeutics Initiates Global Phase...
10/17/2025 11:04:42

HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLCClinical Trial Site Activati...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/08/2025 17:35:32

alpha-buying-the-3-stocks-that-just-got-this-1-million-vote-of-confidence
Alpha Buying: The 3 Stocks That Just Got T...
10/01/2025 18:39:50

intel-marvell-electronic-arts-are-among-the-top-10-large-cap-gainers-last-week-sep-22---sep-26-are-the-others-in-your-portfolio
Intel, Marvell, Electronic Arts Are Among ...
09/28/2025 13:25:51

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

summit-therapeutics-harmoni-6-phase-iii-trial-shows-ivonescimab-plus-chemotherapy-significantly-improves-pfs-over-tislelizumab-in-1l-squamous-nsclc-data-to-be-presented-at-esmo-2025-presidential-symposium
Summit Therapeutics' HARMONi-6 Phase III T...
09/24/2025 11:04:48

nvidia-high-fives-palantir-rocket-lab--on-this-list-of-10-bagger-legends
Nvidia High-Fives Palantir, Rocket Lab — O...
09/23/2025 16:40:29

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom,...

this-protagonist-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Protagonist Therapeutics Analyst Begi...
09/17/2025 12:15:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION